Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ6YXF)

Drug Name

SKF-75670 Drug Info

Synonyms

Skf 75670; 3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol; SKF-75670; AC1L5AM7; Lopac0_001087; GTPL936; SCHEMBL11712694; CHEMBL1193571; BDBM81986; NSC_173870; CCG-205164; CAS_173870; NCGC00162337-01; NCGC00015942-03; NCGC00015942-02; L000564; 3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol; 2,3,4,5-Tetrahydro-3-methyl-1-phenyl-1H-3-benzazepine-7,8-diol; 3-Methyl-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 173871
TTD Drug ID: DMQ6YXF

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dopamine D1 receptor (D1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[3]
Pergolide	DM14MAE	Parkinson disease	8A00.0	Approved	[4]
Methylergonovine	DMBEX4O	Spontaneous abortion	JA00.0	Approved	[5]
Fenoldopam	DMFAOKP	Hypertension	BA00-BA04	Approved	[6]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[7]
Ecopipam	DMS9R43	Cocaine addiction	6C45.2	Phase 3	[8]
DAS-431	DMM3BPL	Dementia	6D80-6D86	Phase 2	[9]
Dihydrexidine	DMACPQO	Psychotic disorder	6A20-6A25	Phase 1/2	[10]
Lu AF28996	DMY572G	Parkinson disease	8A00.0	Phase 1	[11]
BAM-1110	DMPMKUF	Parkinson disease	8A00.0	Discontinued in Phase 2	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D1 receptor (D1R)	TTZFYLI	DRD1_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 936).
2	Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. Eur J Pharmacol. 1990 Jun 12;188(6):335-47.
3	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
6	Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
7	Clinical pipeline report, company report or official report of Lundbeck.
8	A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
9	Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
10	trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
11	Clinical pipeline report, company report or official report of Lundbeck
12	Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.